Figures & data
Figure 2 MTT assay showing that the treatment of ORI nanosuspension and free ORI solution inhibit growth of PC-3 cells in a time- and dose-dependent manner. Results are expressed as mean ± standard deviation (n = 6).
Notes: *P < 0.05, **P < 0.01, ***P < 0.005 versus the same dose of free ORI solution group.
![Figure 2 MTT assay showing that the treatment of ORI nanosuspension and free ORI solution inhibit growth of PC-3 cells in a time- and dose-dependent manner. Results are expressed as mean ± standard deviation (n = 6).Notes: *P < 0.05, **P < 0.01, ***P < 0.005 versus the same dose of free ORI solution group.](/cms/asset/ce94b28c-25ac-4602-bf0e-431ed5f6133c/dijn_a_12184744_f0002_b.jpg)
Table 1 The IC50 values (μmol/L) of oridonin (ORI) nanosuspension and ORI solution on PC-3 cells (n = 6)
Figure 3 The effect of oridonin nanosuspension on apoptosis morphological change of PC-3 cells (X200).
![Figure 3 The effect of oridonin nanosuspension on apoptosis morphological change of PC-3 cells (X200).](/cms/asset/24957ebc-2493-47a8-acdd-12aacc3cf86f/dijn_a_12184744_f0003_c.jpg)
Figure 4 The effect of oridonin nanosuspension on the proliferation cycle of PC-3 cells. A) Control. B) 25 μmol/L ORI solution. C) 25 μmol/L ORI nanosuspension. D) 50 μmol/L ORI solution. E) 50 μmol/L ORI nanosuspension.
![Figure 4 The effect of oridonin nanosuspension on the proliferation cycle of PC-3 cells. A) Control. B) 25 μmol/L ORI solution. C) 25 μmol/L ORI nanosuspension. D) 50 μmol/L ORI solution. E) 50 μmol/L ORI nanosuspension.](/cms/asset/5d1fa18c-0a63-42f3-bdb7-fd9d358e94bd/dijn_a_12184744_f0004_c.jpg)